Chronic Lymphocytic Leukemia Treatment Market Size, Growth and Trends Analysis by Type (Indolent & Aggressive), by Treatment (Chemotherapy, Targeted Drug Therapy, Immunotherapy & Bone Marrow Transplant), by End User (Hospitals & Clinics & Others) - Forecast Till 2027

Chronic Lymphocytic Leukemia (CLL) Treatment Market Scenario:

Chronic Lymphocytic Leukemia (CLL) Treatment Market was valued USD 7.9 Billion in 2017 and is projected to grow at a CAGR of 19% over the forecast period. Chronic Lymphocytic Leukemia is a type of cancer that affects a specific type of white blood cell known as lymphocyte.

The factors such as rising prevalence of leukemia as well as CLL, increasing research & development activities and technological advancements related to the treatment are expected to propel the growth of the market. However, the high cost of treatment and stringent government regulations can hamper the market growth over the forecast period.

Chronic Lymphocytic Leukemia Treatment Market Segmentation:

The Chronic Lymphocytic Leukemia Treatment Market has been segmented into type, treatment and end user. The market, on the basis of type, has been segmented into indolent CLL and aggressive CLL.

The market, by treatment, has been segmented into chemotherapy, targeted drug therapy, immunotherapy and bone marrow transplant.

The market, by end user, has been segmented into hospitals & clinics, diagnostic laboratories, research institutes and others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The chronic lymphocytic leukemia treatment market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European chronic lymphocytic leukemia treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The chronic lymphocytic leukemia treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key players:

Hoffmann-La Roche Ltd, GlaxoSmithKline plc, CELGENE CORPORATION, Genmab A/S, Teva Pharmaceutical Industries Ltd., Genentech, Inc., Genzyme Corporation, AbbVie Inc., Gilead, Novartis AG, Johnson & Johnson Services, Inc., AstraZeneca, ONO PHARMACEUTICAL CO., LTD., TG Therapeutics, Inc., Ziopharm Oncology, Inc. and others are some of the key players in the global chronic lymphocytic leukemia treatment market.

Regional Market Summary:

Chronic Lymphocytic Leukemia Treatment Market Share (%), by Region, 2017

Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, Annual Reports

Geographically, the Americas is anticipated to dominate the global chronic lymphocytic leukemia treatment market owing to rising prevalence of leukemia and presence of major market players. According to a report published by the Leukemia & Lymphoma Society in 2018, every 3 minutes one person in the US is diagnosed with blood cancer (leukemia).

Europe is expected to hold the second largest position in the global chronic lymphocytic leukemia treatment market. The market growth in this region is attributed to rising research and development activities in the field of leukemia. The chronic lymphocytic leukemia treatment market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to the rising prevalence of leukemia and growing demand for treatment of the disease. According to a report published by the World Health Organization in 2017, 8,904 leukemia deaths were reported in Japan.

The Middle East & Africa are expected to hold the least share of the market. The market growth in this region is expected to be driven by a developing healthcare infrastructure.

The Market of Chronic Lymphocytic Leukemia Treatment, by Type:

• Indolent CLL


• Aggressive CLL

The Market of Chronic Lymphocytic Leukemia, by Treatment:

• Chemotherapy


• Targeted Drug Therapy


• Immunotherapy


• Bone Marrow Transplant

The Market of Chronic Lymphocytic Leukemia Treatment, by End User:

• Hospitals and Clinics


• Diagnostic Laboratories


• Research Institutes


• Others

The Market of Chronic Lymphocytic Leukemia Treatment, by Region:

Americas

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• South America

Europe

• Western Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • Italy
  
  
  • Spain
  
  
  • UK
  
  
  • Rest of Western Europe
  
  
  
  


• Eastern Europe

Asia-Pacific

• Japan


• China


• India


• Australia


• South Korea


• Rest of Asia-Pacific

The Middle East & Africa

• Middle East


• Africa

Chronic Lymphocytic Leukemia Treatment Market, by Key Players:

• Hoffmann-La Roche Ltd


• GlaxoSmithKline plc


• CELGENE CORPORATION


• Genmab A/S


• Teva Pharmaceutical Industries Ltd.


• Genentech, Inc.


• Genzyme Corporation


• AbbVie Inc.


• Gilead


• Novartis AG


• Johnson & Johnson Services, Inc.


• AstraZeneca


• ONO PHARMACEUTICAL CO., LTD.


• TG Therapeutics, Inc.


• Ziopharm Oncology, Inc.

Intended Audience:

• Pharmaceutical Companies


• Research Laboratories


• Oncology Laboratories


• Healthcare Organizations

Frequently Asked Questions (FAQ) :

---